As a dual-action GLP-1/GIP agonist, this once-weekly injection shows significant weight loss results, making it suitable for those who have not responded to singular hormone targeting medications
A Dedicated Nurse in Your Corner
Short-chain fatty acids (SCFAs), a recognized microbiota metabolite, interact with enteroendocrine L cells, inducing the production of GLP-2, which contributes to the maintenance of tight junctions between intestinal epithelial cells
But for many, this is the point where the changes on their appetite become easier to recognise and maintain
Membership Includes: Monthly prescription to FDA-approved medication for weight-loss
Of the 216 enrolled patients, 102 (47.2%) were not included in the primary analysis because of incomplete questionnaires or loss to follow-up